Humacyte’s (HUMA) “Buy” Rating Reiterated at HC Wainwright

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $3.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 176.50% from the stock’s current price.

Other research analysts have also issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, April 28th. Wall Street Zen upgraded shares of Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, BTIG Research decreased their price target on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.57.

Humacyte Price Performance

Shares of NASDAQ:HUMA traded up $0.04 during trading on Tuesday, reaching $1.09. The company had a trading volume of 4,349,914 shares, compared to its average volume of 6,454,731. The firm’s fifty day moving average is $0.83 and its 200 day moving average is $1.03. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93. The firm has a market capitalization of $240.89 million, a PE ratio of -1.90 and a beta of 2.31. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.93.

Humacyte (NASDAQ:HUMA) last released its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. On average, equities analysts forecast that Humacyte will post -0.32 EPS for the current year.

Insiders Place Their Bets

In related news, Director Kathleen Sebelius purchased 56,818 shares of Humacyte stock in a transaction on Tuesday, May 19th. The stock was bought at an average price of $0.88 per share, with a total value of $49,999.84. Following the completion of the transaction, the director directly owned 148,025 shares of the company’s stock, valued at approximately $130,262. This represents a 62.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Dale A. Sander sold 45,887 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the sale, the chief financial officer directly owned 267,213 shares of the company’s stock, valued at $240,491.70. This represents a 14.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in shares of Humacyte in the fourth quarter worth about $25,000. Atom Investors LP acquired a new stake in shares of Humacyte in the fourth quarter worth about $25,000. Truist Financial Corp acquired a new stake in shares of Humacyte in the third quarter worth about $28,000. Prudential Financial Inc. acquired a new stake in shares of Humacyte in the second quarter worth about $28,000. Finally, Financial Advisors Network Inc. acquired a new stake in shares of Humacyte in the second quarter worth about $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.